Free tool
FAERS Monitor: Toprol-Xl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019962 or its brand name (Toprol-Xl, Metoprolol Succinate). Reports on generic versions are filed under their own applications.
Reports
88,225
Serious
54,921
62% of reports
Hospitalization
29,946
Death reported
8,049
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue6,628
- diarrhoea5,434
- nausea5,124
- dyspnoea5,068
- drug ineffective4,420
- dizziness4,356
- off label use4,331
- headache4,004
- death3,608
- asthenia3,350
- pain3,286
- fall3,171
- cough2,677
- pneumonia2,660
- malaise2,517
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 589 |
| 2005 | 538 |
| 2006 | 696 |
| 2007 | 1,529 |
| 2008 | 890 |
| 2009 | 1,252 |
| 2010 | 983 |
| 2011 | 1,876 |
| 2012 | 3,087 |
| 2013 | 1,535 |
| 2014 | 4,012 |
| 2015 | 5,011 |
| 2016 | 5,332 |
| 2017 | 5,626 |
| 2018 | 6,458 |
| 2019 | 6,109 |
| 2020 | 5,687 |
| 2021 | 5,015 |
| 2022 | 5,570 |
| 2023 | 5,880 |
| 2024 | 6,865 |
| 2025 | 7,767 |
| 2026 | 5,916 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,965,934 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| coughSignal | 2,677 | 2.3 | 2.2 | 1,947 |
| fallSignal | 3,171 | 2.3 | 2.2 | 2,301 |
| dyspnoeaSignal | 5,068 | 2.1 | 2.1 | 3,152 |
| astheniaSignal | 3,350 | 2.1 | 2.1 | 2,036 |
| dizzinessSignal | 4,356 | 2.1 | 2.0 | 2,519 |
| fatigueSignal | 6,628 | 2.0 | 2.0 | 3,609 |
| diarrhoeaSignal | 5,434 | 2.0 | 2.0 | 2,843 |
| pneumonia | 2,660 | 2.0 | 1.9 | 1,272 |
| nausea | 5,124 | 1.5 | 1.5 | 1,023 |
| headache | 4,004 | 1.5 | 1.5 | 743 |
| malaise | 2,517 | 1.4 | 1.3 | 255 |
| pain | 3,286 | 1.3 | 1.2 | 202 |
| off label use | 4,331 | 1.2 | 1.1 | 123 |
| death | 3,608 | 1.0 | 1.0 | 0 |
| drug ineffective | 4,420 | 0.8 | 0.8 | 238 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.